Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | TNF | P01375 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191422 | 1.00 | MDM4 (0.55) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL31000735 | 1.00 | MDM4 (0.55) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL29401864 | 1.00 | MDM4 (0.55) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL19899314 | 1.00 | MDM4 (0.55) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL31165326 | 1.00 | MDM4 (0.55) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL31037709 | 0.92 | MDM4 (0.49) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL29818551 | 0.90 | MDM4 (0.54) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL29129111 | 0.88 | MDM4 (0.54) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL29129108 | 0.88 | MDM4 (0.54) | MDM4TP53TNFCASP3MDM2 | |
| SCHEMBL29613460 | 0.88 | MDM4 (0.54) | MDM4TP53TNFCASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| EP-3504197-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10870623-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3504197-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185426-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018036957-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
| US-7524883-B2 | Eponemycin and epoxomicin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MDM4 3502/4885TP53 1148/4885TNF 2033/4885 |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | MDM4 4588/4885TP53 3334/4885TNF 4792/4885 |
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | MDM4 3904/4885TP53 1901/4885TNF 226/4885 |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR3E, HTR1F | MDM4 4588/4885TP53 3334/4885TNF 4792/4885 |
| US-20190185426-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTRA2, HTR1A | MDM4 4635/4885TP53 3494/4885TNF 4707/4885 |
| US-10870623-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR1A, HTR1F | MDM4 4638/4885TP53 3731/4885TNF 4757/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | MDM4 1310/4885TP53 1981/4885TNF 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.